MAGEA3 and breast carcinoma: In summary, prior literature suggested breast cancer as a relatively “CT-poor” tumor type, and CT antigen-based therapeutic cancer vaccine trials, e.g. MAGEA3 and NY-ESO-1 trials, have not been actively pursued in breast cancer for this reason.